1. Nicholson, J. K. et al. Host-gut microbiota metabolic interactions.Science 336, 1262–1267 (2012).
2. Sender, R., Fuchs, S. & Milo, R. Revised Estimates for the Number of Human and Bacteria Cells in the Body. PLoS Biol. 14, e1002533 (2016).
3. Wikoff, W. R. et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc. Natl. Acad. Sci. U.S. A. 106, 3698–3703 (2009).
4. Laukens, D. et al. Heterogeneity of the gut microbiome in mice: Guidelines for optimizing experimental design. FEMS Microbiol. Rev. 40, 117–132 (2015).
5. Clemente, J. C., Ursell, L. K., Parfrey, L. W. & Knight, R. The impact of the gut microbiota on human health: An integrative view. Cell 148, 1258–1270 (2012).
6. Meijers, B. K. I. & Evenepoel, P. The gut-kidney axis: Indoxyl sulfate, p-cresyl sulfate and CKD progression. Nephrol. Dial. Transplant. 26, 759–761 (2011).
7. Toyohara, T. et al. Metabolomic profiling of uremic solutes in CKD patients. Hypertens. Res. 33, 944–952 (2010).
8. Kimura, T. et al. Identification of biomarkers for development of end- stage kidney disease in chronic kidney disease by metabolomic profiling. Sci. Rep. 6, 26138 (2016).
9. Meyer, T. W. & Hostetter, T. H. Uremia. N. Engl. J. Med. 357, 1316– 1325 (2007).
10. Depner, T. A. Uremic Toxicity: Urea and Beyond. Semin. Dial. 14, 246–251 (2008).
11. Liabeuf, S., Drüeke, T. B., Massy, Z. A. & Studies, C. Protein-bound uremic toxins: New insight from clinical studies. Toxins (Basel). 3, 911–919 (2011).
12. Vanholder, R., Schepers, E., Pletinck, A., Nagler, E. V & Glorieux, G. The Uremic Toxicity of Indoxyl Sulfate and p-Cresyl Sulfate: A Systematic Review. J. Am. Soc. Nephrol. 25, 1897–1907 (2014).
13. Vanholder, R., Laecke, S. Van & Glorieux, G. What is new in uremic toxicity? Pediatr. Nephrol. 23, 1211–1221 (2008).
14. Vanholder, R. et al. Review on uremic toxins: Classification, concentration, and interindividual variability. Kidney Int. 63, 1934– 1943 (2003).
15. Wang, Z. et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472, 57–63 (2011).
16. Missailidis, C. et al. Serum Trimethylamine-N-Oxide Is Strongly Related to Renal Function and Predicts Outcome in Chronic Kidney Disease. PLoS One 11, e0141738 (2016).
17. Stubbs, J. R. et al. Serum Trimethylamine- N -Oxide is Elevated in CKD and Correlates with Coronary Atherosclerosis Burden. J. Am. Soc. Nephrol. 27, 305–313 (2016).
18. Wu, I. W. et al. P-cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Nephrol. Dial. Transplant. 26, 938–947 (2011).
19. Barreto, F. C. et al. Serum Indoxyl Sulfate Is Associated with Vascular Disease and Mortality in Chronic Kidney Disease Patients. Clin J Am Soc Nephrol 4, 1551–1558 (2009).
20. Liabeuf, S. et al. Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol. Dial. Transplant. 25, 1183–1191 (2010).
21. Lin, C. J., Wu, V., Wu, P. C. & Wu, C. J. Meta-analysis of the associations of p-cresyl sulfate (PCS) and indoxyl sulfate (IS) with cardiovascular events and all-cause mortality in patients with chronic renal failure. PLoS One 10, 1–14 (2015).
22. Meyer, T. W. & Hostetter, T. H. Uremic solutes from colon microbes.Kidney Int. 81, 949–954 (2012).
23. Tanaka, H., Sirich, T. L., Meyer, T. W., Sirich, L. & Meyer, T. W. Uremic Solutes Produced by Colon Microbes. Blood Purif. 40, 306–311 (2015).
24. W.H. Wilson Tang, Zeneng Wang, Bruce S. Levison, Robert A. Koeth, Earl B. Britt, Xiaoming Fu, Yuping Wu, S. L. H. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. New Engl.J. Med. 368, 1575–1584 (2013).
25. Poesen, R. et al. The influence of dietary protein intake on mammalian tryptophan and phenolic metabolites. PLoS One 10, 1–12 (2015).
26. Kishino, S. et al. Polyunsaturated fatty acid saturation by gut lactic acid bacteria affecting host lipid composition. Proc. Natl. Acad. Sci. 110, 17808–17813 (2013).
27. Miyamoto, T. et al. Argininosuccinate synthase 1 is an intrinsic Akt repressor transactivated by p53. Sci. Adv. 3, e1603204 (2017).
28. Maslowski, K. M. et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 461, 1282– 1286 (2009).
29. Vaziri, N. D. et al. High amylose resistant starch diet ameliorates oxidative stress, inflammation, and progression of chronic kidney disease. PLoS One 9, e114881 (2014).
30. Andrade-Oliveira, V. et al. Gut Bacteria Products Prevent AKI Induced by Ischemia-Reperfusion. J. Am. Soc. Nephrol. 26, 1877–1888 (2015).
31. Nakade, Y. et al. Gut microbiota–derived D-serine protects against acute kidney injury. JCI Insight 3, e97957 (2018).
32. Chen, D. Q. et al. Identification of serum metabolites associating with chronic kidney disease progression and anti-fibrotic effect of 5- methoxytryptophan. Nat. Commun. 10, 1–15 (2019).
33. Vaziri, N. D. et al. Chronic kidney disease alters intestinal microbial flora. Kidney Int 83, 308–315 (2013).
34. Yoshifuji, A. et al. Gut Lactobacillus protects against the progression of renal damage by modulating the gut environment in rats. Nephrol. Dial. Transplant. 31, 401–412 (2016).
35. Wong, J. et al. Expansion of urease- and uricase-containing, indole- and p-cresol-forming and contraction of short-chain fatty acid- producing intestinal microbiota in ESRD. Am. J. Nephrol. 39, 230–237 (2014).
36. Kaliannan, K., Wang, B., Li, X.-Y., Kim, K.-J. & Kang, J. X. A host- microbiome interaction mediates the opposing effects of omega-6 and omega-3 fatty acids on metabolic endotoxemia. Sci. Rep. 5, 11276 (2015).
37. Anders, H. J., Andersen, K. & Stecher, B. The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease. Kidney Int 83, 1010–1016 (2013).
38. Vaziri, N. D. et al. Disintegration of colonic epithelial tight junction in uremia: A likely cause of CKD-associated inflammation. Nephrol. Dial. Transplant. 27, 2686–2693 (2012).
39. Cosola, C. et al. Microbiota metabolites: Pivotal players of cardiovascular damage in chronic kidney disease. Pharmacol. Res. 130, 132–142 (2018).
40. Just, S. et al. The gut microbiota drives the impact of bile acids and fat source in diet on mouse metabolism. Microbiome 6, 1–18 (2018).
41. Koppel, N., Maini Rekdal, V. & Balskus, E. P. Chemical transformation of xenobiotics by the human gut microbiota. Science 356, eaag2770 (2017).
42. Mishima, E. et al. Evaluation of the impact of gut microbiota on uremic solute accumulation by a CE-TOFMS-based metabolomics approach. Kidney Int. 92, 634–645 (2017).
43. Itoh, Y., Ezawa, A., Kikuchi, K., Tsuruta, Y. & Niwa, T. Correlation between Serum Levels of Protein-Bound Uremic Toxins in Hemodialysis Patients Measured by LC/MS/MS. Mass Spectrom. (Tokyo, Japan) 2, S0017 (2013).
44. Niwa, T. Update of uremic toxin research by mass spectrometry. Mass Spectrom. Rev. 30, 510–521 (2011).
45. Shu, C. et al. LC-MS/MS method for simultaneous determination of serum p-cresyl sulfate and indoxyl sulfate in patients undergoing peritoneal dialysis. Biomed. Chromatogr. 30, 1782–1788 (2016).
46. Kikuchi, K. et al. Gut microbiome-derived phenyl sulfate contributes to albuminuria in diabetic kidney disease. Nat. Commun. 10, 1835 (2019).
47. Jang, H. R. et al. Early exposure to germs modifies kidney damage and inflammation after experimental ischemia-reperfusion injury. Am.J. Physiol. Physiol. 297, F1457–F1465 (2009).
48. Emal, D. et al. Depletion of Gut Microbiota Protects against Renal Ischemia-Reperfusion Injury. J. Am. Soc. Nephrol. 28, 1450–1461 (2017).
49. Andersen, K. et al. Intestinal Dysbiosis, Barrier Dysfunction, and Bacterial Translocation Account for CKD–Related Systemic Inflammation. J. Am. Soc. Nephrol. 28, 76–83 (2017).
50. Kikuchi, K. et al. Metabolomic analysis of uremic toxins by liquid chromatography/electrospray ionization-tandem mass spectrometry. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 878, 1662–1668 (2010).
51. Kobayashi, T. et al. Exploration of novel predictive markers in rat plasma of the early stages of chronic renal failure. Anal. Bioanal. Chem. 406, 1365–1376 (2014).
52. Kikuchi, K. et al. Metabolomic search for uremic toxins as indicators of the effect of an oral sorbent AST-120 by liquid chromatography/tandem mass spectrometry. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 878, 2997–3002 (2010).
53. Hsiao, E. Y. et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell 155, 1451–1463 (2013).
54. Mishima, E. et al. Conformational Change in Transfer RNA Is an Early Indicator of Acute Cellular Damage. J. Am. Soc. Nephrol. 25, 2316–2326 (2014).
55. van den Brand, J. A. J. G. et al. Uremic Solutes in Chronic Kidney Disease and Their Role in Progression. PLoS One 11, e0168117 (2016).
56. de Loor, H. et al. A liquid chromatography – tandem mass spectrometry method to measure a selected panel of uremic retention solutes derived from endogenous and colonic microbial metabolism. Anal. Chim. Acta 936, 149–156 (2016).
57. Boelaert, J. et al. Metabolic profiling of human plasma and urine in chronic kidney disease by hydrophilic interaction liquid chromatography coupled with time-of-flight mass spectrometry: a pilot study. Anal. Bioanal. Chem. 409, 2201–2211 (2017).
58. Ocque, A. J., Stubbs, J. R. & Nolin, T. D. Development and validation of a simple UHPLC-MS/MS method for the simultaneous determination of trimethylamine N-oxide, choline, and betaine in human plasma and urine. J. Pharm. Biomed. Anal. 109, 128–135 (2015).
59. Fraselle, S. et al. Development and validation of an ultra-high performance liquid chromatography-tandem mass spectrometry method to measure creatinine in human urine. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 988, 88–97 (2015).
60. Wang, L. et al. Recent advances in materials for stationary phases of mixed-mode high-performance liquid chromatography. TrAC - Trends Anal. Chem. 80, 495–506 (2016).
61. Qiu, H. et al. New poly(ionic liquid)-grafted silica multi-mode stationary phase for anion-exchange/reversed-phase/hydrophilic interaction liquid chromatography. Analyst 137, 2553–2555 (2012).
62. Cai, X. et al. Two-dimensional liquid chromatography separation of peptides using reversed-phase/weak cation-exchange mixed-mode column in first dimension. J. Chromatogr. A 1228, 242–249 (2012).
63. Biba, M. et al. Factors influencing the separation of oligonucleotides using reversed-phase/ion-exchange mixed-mode high performance liquid chromatography columns. J. Chromatogr. A 1304, 69–77 (2013).
64. Kazarian, A. A. et al. Comprehensive analysis of pharmaceutical products using simultaneous mixed-mode (ion-exchange/reversed- phase) and hydrophilic interaction liquid chromatography. J. Sep. Sci. 37, 2138–2144 (2014).
65. Choi, H. et al. Development of an analytical method for simultaneous detection of psychotropic phenylalkylamines in hair by LC-MS/MS with a multi-mode reversed-phase column using pH gradient elution. Forensic Sci. Int. 259, 69–76 (2016).
66. Ordoñez, E. Y. et al. Computer assisted optimization of liquid chromatographic separations of small molecules using mixed-mode stationary phases. J. Chromatogr. A 1238, 91–104 (2012).
67. Yamagaki, T. Fundamentals of Electrospray Ionization in LC/MS. J. Mass Spectrom. Soc. Jpn. 65, 11–16 (2017).
68. Taylor, P. J. Matrix effects: The Achilles heel of quantitative high- performance liquid chromatography-electrospray-tandem mass spectrometry. Clin. Biochem. 38, 328–334 (2005).
69. Hewavitharana, A. K. Matrix matching in liquid chromatography- mass spectrometry with stable isotope labelled internal standards-Is it necessary? J. Chromatogr. A 1218, 359–361 (2011).
70. Annesley, T. M. Ion suppression in mass spectrometry. Clin. Chem.49, 1041–1044 (2003).
71. Edwards, D. R., Lohman, D. C. & Wolfenden, R. Catalytic Proficiency: The Extreme Case of S–O Cleaving Sulfatases. J. Am. Chem. Soc. 134, 525–531 (2012).
72. Sajiki, H. et al. Complete replacement of H2 by D2 via Pd/C-catalyzedH/D exchange reaction. Org. Lett. 6, 3521–3523 (2004).
73. Sajiki, H. et al. Aromatic ring favorable and efficient H-D exchange reaction catalyzed by Pt/C. Tetrahedron Lett. 46, 6995–6998 (2005).
74. Esaki, H. et al. General method of obtaining deuterium-labeled heterocyclic compounds using neutral D2O with heterogeneous Pd/C. Tetrahedron 62, 10954–10961 (2006).
75. Sajiki, H., Esaki, H., Aoki, F., Maegawa, T. & Hirota, K. Palladium- catalyzed base-selective H-D exchange reaction of nucleosides in deuterium oxide. Synlett 2005, 1385–1388 (2005).
76. Itoh, Y., Ezawa, A., Kikuchi, K., Tsuruta, Y. & Niwa, T. Protein-bound uremic toxins in hemodialysis patients measured by liquid chromatography/tandem mass spectrometry and their effects on endothelial ROS production. Anal. Bioanal. Chem. 403, 1841–1850 (2012).
77. Boelaert, J. et al. A novel UPLC-MS-MS method for simultaneous determination of seven uremic retention toxins with cardiovascular relevance in chronic kidney disease patients. Anal. Bioanal. Chem. 405, 1937–1947 (2013).
78. Sabatino, A. et al. Alterations of intestinal barrier and microbiota in chronic kidney disease. Nephrol. Dial. Transplant. 30, 924–933 (2015).
79. Rossi, M. et al. Synbiotics Easing Renal Failure by Improving Gut Microbiology (SYNERGY): A Randomized Trial. Clin. J. Am. Soc. Nephrol. 11, 223–231 (2016).
80. Yamamoto, S. et al. Continuous Reduction of Protein-Bound Uraemic Toxins with Improved Oxidative Stress by Using the Oral Charcoal Adsorbent AST-120 in Haemodialysis Patients. Sci. Rep. 5, 14381 (2015).
81. Wang, Z. et al. Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis. Cell 163, 1585–1595 (2015).
82. Mishima, E. et al. Canagliflozin reduces plasma uremic toxins and alters the intestinal microbiota composition in a chronic kidney disease mouse model. Am. J. Physiol. Physiol. 315, F824–F833 (2018).
83. James, M. T., Hemmelgarn, B. R. & Tonelli, M. Early recognition and prevention of chronic kidney disease. Lancet 375, 1296–1309 (2010).
84. Wouters, O. J., O’Donoghue, D. J., Ritchie, J., Kanavos, P. G. & Narva,A. S. Early chronic kidney disease: diagnosis, management and models of care. Nat. Rev. Nephrol. 11, 491–502 (2015).
85. Bone, E., Tamm, A. & Hill, M. The production of urinary phenols by gut bacteria and their possible role in the causation of large bowel cancer. Am. J. Clin. Nutr. 29, 1448–1454 (1976).
86. Smith, E. A. A. & Macfarlane, G. T. T. Formation of phenolic and indolic compounds by anerobic bacteria in the human large intestine. Microb. Ecol. 33, 180–188 (1997).
87. Wang, T. J. et al. Metabolite profiles and the risk of developing diabetes. Nat. Med. 17, 448–453 (2011).
88. Ogata, M. & Yamasaki, Y. High Performance Liquid Chromatography for the Quantitative Determination of Urinary Phenylsulfate and Phenylglucuronide as Indices of Benzene and Phenol Exposure in Rats. Int. Arch. Occup. Environ. Health 44, 177–184 (1979).
89. Ogata, M. & Taguchi, T. Simultaneous determination of urinary creatinine and metabolites of toluene, xylene, styrene, ethylbenzene and phenol by automated high performance liquid chromatography. Int. Arch. Occup. Environ. Health 61, 131–140 (1988).
90. Pierce, W. M. & Nerland, D. E. Qualitative and Quantitative Analyses of Phenol, Phenylglucuronide, and Phenylsulfate in Urine and Plasma by Gas Chromatography/Mass Spectrometry. J. Anal. Toxicol. 12, 344– 347 (1988).
91. Miyazaki, T., Aoyama, I., Ise, M., Seo, H. & Niwa, T. An oral sorbent reduces overload of indoxyl sulphate and gene expression of TGF- beta1 in uraemic rat kidneys. Nephrol. Dial. Transplant 15, 1773– 1781 (2000).
92. Kohl, T. O. & Ascoli, C. A. Indirect Immunometric ELISA. Cold Spring Harb. Protoc. 2017, pdb.prot093708 (2017).
93. Yang, F. et al. Competitive immunoassay for analysis of bisphenol A in children’s sera using a specific antibody. Environ. Sci. Pollut. Res. 23, 10714–10721 (2016).
94. Zampieri, S. et al. The use of Tween 20 in immunoblotting assays for the detection of autoantibodies in connective tissue diseases. J. Immunol. Methods 239, 1–11 (2000).
95. Ridlon, J. M., Kang, D. & Hylemon, P. B. Bile salt biotransformations by human intestinal bacteria. J. Lipid Res. 47, 241–259 (2006).
96. Koh, A., De Vadder, F., Kovatcheva-Datchary, P. & Bäckhed, F. From dietary fiber to host physiology: Short-chain fatty acids as key bacterial metabolites. Cell 165, 1332–1345 (2016).
97. Spaepen, S., Vanderleyden, J. & Remans, R. Indole-3-acetic acid in microbial and microorganism-plant signaling. FEMS Microbiol. Rev. 31, 425–448 (2007).
98. Wahlström, A., Sayin, S. I., Marschall, H. U. & Bäckhed, F. Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism. Cell Metab. 24, 41–50 (2016).
99. Want, E. J. et al. Global metabolic profiling procedures for urine using UPLC-MS. Nat. Protoc. 5, 1005–1018 (2010).
100. Saigusa, D. et al. Establishment of protocols for global metabolomics by LC-MS for biomarker discovery. PLoS One 11, 1–18 (2016).
101. Higashi, T. & Ogawa, S. Isotope-coded ESI-enhancing derivatization reagents for differential analysis, quantification and profiling of metabolites in biological samples by LC/MS: A review. J. Pharm. Biomed. Anal. 130, 181–193 (2016).
102. Yuan, B. F. et al. Comprehensive Profiling of Fecal Metabolome of Mice by Integrated Chemical Isotope Labeling-Mass Spectrometry Analysis. Anal. Chem. 90, 3512–3520 (2018).
103. Guo, N., Peng, C. Y., Zhu, Q. F., Yuan, B. F. & Feng, Y. Q. Profiling of carbonyl compounds in serum by stable isotope labeling - Double precursor ion scan - Mass spectrometry analysis. Anal. Chim. Acta 967, 42–51 (2017).
104. Lu, Y., Yao, D. & Chen, C. 2-Hydrazinoquinoline as a Derivatization Agent for LC-MS-Based Metabolomic Investigation of Diabetic Ketoacidosis. Metabolites 3, 993–1010 (2013).
105. Guo, K. & Li, L. High-performance isotope labeling for profiling carboxylic acid-containing metabolites in biofluids by mass spectrometry. Anal. Chem. 82, 8789–8793 (2010).
106. Han, J., Lin, K., Sequeira, C. & Borchers, C. H. An isotope-labeled chemical derivatization method for the quantitation of short-chain fatty acids in human feces by liquid chromatography-tandem mass spectrometry. Anal. Chim. Acta 854, 86–94 (2015).
107. Leng, J. et al. A highly sensitive isotope-coded derivatization method and its application for the mass spectrometric analysis of analytes containing the carboxyl group. Anal. Chim. Acta 758, 114–121 (2013).
108. Cai, T., Ting, H., Xin-Xiang, Z., Jiang, Z. & Jin-Lan, Z. HPLC-MRM relative quantification analysis of fatty acids based on a novel derivatization strategy. Analyst 139, 6154–6159 (2014).
109. Zhu, Q. F. et al. Analysis of liposoluble carboxylic acids metabolome in human serum by stable isotope labeling coupled with liquid chromatography–mass spectrometry. J. Chromatogr. A 1460, 100–109 (2016).
110. Zhu, Y., Deng, P. & Zhong, D. Derivatization methods for LC-MS analysis of endogenous compounds. Bioanalysis 7, 2557–2581 (2015).
111. Higashi, T. et al. Simple and practical derivatization procedure for enhanced detection of carboxylic acids in liquid chromatography– electrospray ionization-tandem mass spectrometry. J. Pharm. Biomed. Anal. 52, 809–818 (2010).
112. Joo, K. M. et al. A rapid and highly sensitive UPLC-MS/MS method using pre-column derivatization with 2-picolylamine for intravenous and percutaneous pharmacokinetics of valproic acid in rats. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 938, 35–42 (2013).
113. Nagatomo, R., Okada, Y., Ichimura, M., Tsuneyama, K. & Inoue, K. Application of 2-Picolylamine Derivatized Ultra-high Performance Liquid Chromatography Tandem Mass Spectrometry for the Determination of Short-chain Fatty Acids in Feces Samples. Anal. Sci. 34, 1031–1036 (2018).
114. Maegawa, T., Ito, N., Oono, K., Monguchi, Y. & Sajiki, H. Bimetallic Palladium-Platinum-on-Carbon-Catalyzed H-D Exchange Reaction: Synergistic Effect on Multiple Deuterium Incorporation. Synthesis (Stuttg). 2009, 2674–2678 (2009).
115. Zeng, M. & Cao, H. Fast quantification of short chain fatty acids and ketone bodies by liquid chromatography-tandem mass spectrometry after facile derivatization coupled with liquid-liquid extraction. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 1083, 137–145 (2018).
116. McDonald, G. R. et al. Bioactive contaminants leach from disposable laboratory plasticware. Science (80-. ). 322, 917 (2008).
117. Stewart, J., Drexler, D. M., Leet, J. E., McNaney, C. A. & Herbst, J. J. Labware additives identified to be selective monoamine oxidase-b inhibitors. J. Biomol. Screen. 19, 1409–1414 (2014).
118. Kuno, T., Hirayama-Kurogi, M., Ito, S. & Ohtsuki, S. Reduction in hepatic secondary bile acids caused by short-term antibiotic-induced dysbiosis decreases mouse serum glucose and triglyceride levels. Sci. Rep. 8, 1253 (2018).
119. Kindt, A. et al. The gut microbiota promotes hepatic fatty acid desaturation and elongation in mice. Nat. Commun. 9, 3760 (2018).
120. Tanos, R., Murray, I. A., Smith, P. B., Patterson, A. & Perdew, G. H. Role of the Ah receptor in homeostatic control of fatty acid synthesis in the liver. Toxicol. Sci. 129, 372–379 (2012).
121. Krishnan, S. et al. Gut Microbiota-Derived Tryptophan Metabolites Modulate Inflammatory Response in Hepatocytes and Macrophages. Cell Rep. 23, 1099–1111 (2018).
122. Shearer, G. C., Carrero, J. J., Heimbürger, O., Barany, P. & Stenvinkel, P. Plasma Fatty Acids in Chronic Kidney Disease: Nervonic Acid Predicts Mortality. J. Ren. Nutr. 22, 277–283 (2012).
123. Nallu, A., Sharma, S., Ramezani, A., Muralidharan, J. & Raj, D. Gut microbiome in chronic kidney disease: challenges and opportunities. Transl. Res. 179, 24–37 (2017).
124. Veldhoen, M. & Brucklacher-Waldert, V. Dietary influences on intestinal immunity. Nat. Rev. Immunol. 12, 696–708 (2012).
125. Turolo, S. et al. Fatty Acids in Nephrotic Syndrome and Chronic Kidney Disease. J. Ren. Nutr. 28, 145–155 (2018).
126. Nanto-Hara, F. et al. The guanylate cyclase C agonist linaclotide ameliorates the gut-cardio-renal axis in an adenine-induced mouse model of chronic kidney disease. Nephrol. Dial. Transplant 1–14 (2019). doi:10.1093/ndt/gfz126
127. Transl, J. et al. Aryl hydrocarbon receptor activation mediates kidney disease and renal cell carcinoma. J. Transl. Med. 2, 1–14 (2019).
128. Jia, W. et al. Melamine-induced renal toxicity is mediated by the gut microbiota. Sci. Transl. Med. 5, 1–10 (2013).
129. De Angelis, M. et al. Microbiota and metabolome associated with Immunoglobulin A Nephropathy (IgAN). PLoS One 9, (2014).
130. Feng, Y.-L. et al. Microbiome–metabolomics reveals gut microbiota associated with glycine-conjugated metabolites and polyamine metabolism in chronic kidney disease. Cell. Mol. Life Sci. 76, 4961– 4978 (2019).